DOI: 10.36347/sjams.2022.v10i07.004

Pages: 1054-1057

Background: Recently lower dosages of lignocaine and labetalol have been proven to be beneficial in reducing perioperative adverse cardiovascular events. Objective: In this study our main goal is to evaluate the outcome of lignocaine HCL, and labetalol HCL in low doses for attenuation of hemodynamic response to laryngoscopy and intubation. Method: This prospective study was done at tertiary hospital from January 2020 to December 2021. In this study 100 consenting patients of age group 31–60 years of either sex and various general surgical procedures under endotracheal anesthesia were included in this study. During the study, 100 patients were randomly divided into two groups depending on the study drug to be given: Group LB: Injection labetalol HCL 0.25 mg/kg body weight diluted to 10 ml with 0.9% saline was given IV 5 min before intubation over 60 s, n=50 and Group LG: Injection lignocaine HCL 1 mg/kg body weight diluted to 10 ml with 0.9% saline was given IV 5 min before intubation over 60 s, n=50. Results: during the study, majority were belonged to 41-50 years age group and 60% were male. The increase in mean HR was observed in LG groups but least in labetalol group. Besides that, increase in SBP in group lignocaine but not in labetalol group whereas DBP increased in all both groups almost similarly. RPP in peri-intubation period was most stable in group LB whereas mean atrial pressure increase in group LG was higher than that in group LB. Conclusion: Labetalol was found to be superior for the reduction of HR, SBP, DBP, mean arterial pressure, and RPP during and after laryngoscopy and endotracheal intubation in both intra- and inter-group comparisons.